Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M818Revenue $M4.9Net Margin (%)-17,560.3Altman Z-Score-1.9
Enterprise Value $M649EPS $-5.2Operating Margin %-17,572.6Piotroski F-Score1
P/E(ttm)--Beneish M-Score4.4Pre-tax Margin (%)-17,560.3Higher ROA y-yN
Price/Book4.310-y EBITDA Growth Rate %2.4Quick Ratio3.6Cash flow > EarningsY
Price/Sales5975-y EBITDA Growth Rate %36.1Current Ratio3.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-118.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.7ROIC % (ttm)-590.1Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 17.926%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 17.92-20%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 17.92-43%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 17.92-29%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 17.92-39%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 17.92-53%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 17.92-38%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 17.92-33%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.46)
$ 17.92177%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.94)
$ 17.92263%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 17.92128%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 17.9285%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.280.43view
Barry RichardDirector 2016-03-14Buy75,000$15.664.41view
Price Ben GilDirector 2016-03-14Buy4,500$16.7-2.1view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.8238.32view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.8238.32view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9517.2view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5630.18view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-55.86view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-53.25view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-49.97view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Sarepta shares soar after upgrade implies 322% upside May 02 2016
Jim Cramer -- Following Nelson Peltz Can Make You a Ton of Money May 02 2016
Cramer's Stop Trading: Sarepta May 02 2016
5 Companies That Destroyed Shareholders Last Week May 01 2016
Will Sarepta Therapeutics (SRPT) Stock Be Hurt by Jefferies Downgrade? Apr 29 2016
Jefferies Cuts Sarepta To Sell, Sees Little Chance Of FDA Approval Apr 29 2016
Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital,... Apr 29 2016
Sarepta: FDA Policy Forced AdCom To Vote Against Patients' Interests Apr 29 2016
Sarepta Therapeutics downgraded by Jefferies Apr 29 2016
[$$] Mental Dystrophy at the FDA Apr 28 2016
[$$] Mental Dystrophy at the FDA Apr 28 2016
Sarepta Jumps On Hopes For Muscular Dystrophy Drug Apr 28 2016
Is XBI Heading Back to Where It Started in April? Apr 28 2016
Why Are Investors Piling Into These Surging Stocks? Apr 28 2016
Jim Cramer -- Will FDA Approve Sarepta's Duchenne Drug After All? Apr 28 2016
Sarepta Can Win Speedy FDA Drug Approval Apr 28 2016
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Apr 28 2016
Cramer's Mad Dash: Sarepta & PayPal Apr 28 2016
Sarepta Therapeutics shares surge 20% after article suggests drug approval possible Apr 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)